Biotech Values

[DewDiligence]

PTLA—I presume that the Lovenox label of 10 days is sized to switch off drug when the on-going risk of bleeds starts to outweigh the ever decreasing risk of VTE. Any competitor drug should be judged the same way…

I think you’re overanalyzing the situation. The FDA label for Lovenox used as an inpatient treatment for primary VTE prevention in immobilized patents specifies a duration of 14 days (not 10 days ±4 days as PTLA says) because that’s the approximate length of a typical hospital stay for this patient pool. The 14-day duration is not derived from a tradeoff of thrombosis prevention vs bleeding risk, as you posited.

When patients leave the hospital, they are often transitioned from Lovenox to an oral anticoagulant.